DI
BBC icon

DAGCO Inc’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

DAGCO Inc’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-802
Closed -$19.6K – 235
2023
Q4 		$19.6K Buy
+802
New +$15.8K 0.02% 168

Other funds holding BBC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
DWS
Dynamic Wealth Strategies Granite Bay, California $173M AUM 14.19% 1-Year Est. Return
DSC
Duncker Streett & Co St. Louis, Missouri $526M AUM 22.2% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

DAGCO Inc's BBC Position: Q1 2024 in Review

DAGCO Inc sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q1 2024, closing a stake of 802 shares — an estimated $19.6K sold.

DAGCO Inc first reported a position in BBC in Q4 2023 and held it in 1 quarter. The position peaked at $19.6K in Q4 2023. 17 funds tracked by Wall St. Rank hold BBC as of Q1 2024.

  • DAGCO Inc reported no remaining Virtus Biotech Clinical Trials ETF position as of Q1 2024 after selling out during the quarter.
  • DAGCO Inc sold 802 Virtus Biotech Clinical Trials ETF shares in Q1 2024, an estimated $19.6K.
  • DAGCO Inc first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2023 and held it in 1 quarter.
  • DAGCO Inc's Virtus Biotech Clinical Trials ETF position peaked at $19.6K in Q4 2023.
  • 17 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q1 2024.

Based on DAGCO Inc's 13F filing for Q1 2024, filed 15 May 2024.